Covered recipient · General Payments record
NICHOLAS WALTER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2019
$830.79
- Reported across 42 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2019 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $382.88 | 17 |
By paying entity
PY2019 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $267.49 | 9 |
| PFIZER INC. | $53.06 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.00 | 1 |
| Ultragenyx Pharmaceutical Inc. | $15.71 | 1 |
| Acerta Pharma LLC | $14.93 | 1 |
| GlaxoSmithKline, LLC. | $13.69 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2019 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $18.15 | 01/18/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829585 | CMS |
| Amgen Inc. | $4.90 | 02/06/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829587 | CMS |
| Amgen Inc. | $15.56 | 02/22/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829591 | CMS |
| Amgen Inc. | $22.25 | 03/07/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829593 | CMS |
| Amgen Inc. | $117.17 | 03/28/2019 | Food and Beverage | Undisputed | 01/23/2026 | 663341295 | CMS |
| Amgen Inc. | $18.79 | 05/13/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829573 | CMS |
| Amgen Inc. | $17.09 | 06/10/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829575 | CMS |
| Amgen Inc. | $25.63 | 07/15/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829579 | CMS |
| Amgen Inc. | $27.95 | 09/12/2019 | Food and Beverage | Undisputed | 01/23/2026 | 662829581 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.93 | 04/16/2019 | Food and Beverage | Undisputed | 01/23/2026 | 685816485 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.00 | 03/12/2019 | Food and Beverage | Undisputed | 01/23/2026 | 700224975 | CMS |
| GlaxoSmithKline, LLC. | $13.69 | 03/07/2019 | Food and Beverage | Undisputed | 01/23/2026 | 671259779 | CMS |
| PFIZER INC. | $12.61 | 02/25/2019 | Food and Beverage | Undisputed | 01/23/2026 | 671878327 | CMS |
| PFIZER INC. | $13.09 | 05/06/2019 | Food and Beverage | Undisputed | 01/23/2026 | 672076463 | CMS |
| PFIZER INC. | $13.68 | 08/15/2019 | Food and Beverage | Undisputed | 01/23/2026 | 672514659 | CMS |
| PFIZER INC. | $13.68 | 09/04/2019 | Food and Beverage | Undisputed | 01/23/2026 | 672863037 | CMS |
| Ultragenyx Pharmaceutical Inc. | $15.71 | 05/09/2019 | Food and Beverage | Undisputed | 01/23/2026 | 703132557 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019
- Source files
- Dataset page · Bulk file · PY2018 , PY2019
- Generated from
- OP_DTL_GNRL_PGYR2019_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.